EA201790785A1 - Производные тетрагидроизохинолина - Google Patents

Производные тетрагидроизохинолина

Info

Publication number
EA201790785A1
EA201790785A1 EA201790785A EA201790785A EA201790785A1 EA 201790785 A1 EA201790785 A1 EA 201790785A1 EA 201790785 A EA201790785 A EA 201790785A EA 201790785 A EA201790785 A EA 201790785A EA 201790785 A1 EA201790785 A1 EA 201790785A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
tetrahydroisoquinoline
pharmaceuticals
diseases
role
Prior art date
Application number
EA201790785A
Other languages
English (en)
Other versions
EA035544B1 (ru
Inventor
Анне Валаде
Эрик Жноф
Али Ате
Пьерр Бюрссан
Давид Скольц
Бенуа Матьё
Зара Санд
Original Assignee
Юсб Байофарма Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Байофарма Спрл filed Critical Юсб Байофарма Спрл
Publication of EA201790785A1 publication Critical patent/EA201790785A1/ru
Publication of EA035544B1 publication Critical patent/EA035544B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

В заявке описаны производные тетрагидроизохинолина формулы Iкоторые являются позитивными аллостерическими модуляторами D1 и поэтому полезны для применения в качестве фармацевтических средств, предназначенных для лечения заболеваний, в которых играют роль рецепторы D1.
EA201790785A 2014-10-08 2015-10-06 Производные тетрагидроизохинолина EA035544B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14188174 2014-10-08
PCT/EP2015/073053 WO2016055479A1 (en) 2014-10-08 2015-10-06 Tetrahydroisoquinoline derivatives

Publications (2)

Publication Number Publication Date
EA201790785A1 true EA201790785A1 (ru) 2017-10-31
EA035544B1 EA035544B1 (ru) 2020-07-03

Family

ID=51790569

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790785A EA035544B1 (ru) 2014-10-08 2015-10-06 Производные тетрагидроизохинолина

Country Status (18)

Country Link
US (1) US10105359B2 (ru)
EP (1) EP3204359B1 (ru)
JP (1) JP6622299B2 (ru)
CN (1) CN107001278B (ru)
BR (1) BR112017007123B1 (ru)
CA (1) CA2963951C (ru)
CY (1) CY1123417T1 (ru)
DK (1) DK3204359T3 (ru)
EA (1) EA035544B1 (ru)
ES (1) ES2821821T3 (ru)
HR (1) HRP20201469T1 (ru)
HU (1) HUE050664T2 (ru)
LT (1) LT3204359T (ru)
PL (1) PL3204359T3 (ru)
PT (1) PT3204359T (ru)
RS (1) RS60933B1 (ru)
SI (1) SI3204359T1 (ru)
WO (1) WO2016055479A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017222958B2 (en) * 2016-02-25 2019-07-18 Asceneuron S. A. Glycosidase inhibitors
CN108884050B (zh) * 2016-04-13 2022-07-05 Ucb生物制药私人有限公司 四氢异喹啉衍生物
CN107698433A (zh) * 2017-09-12 2018-02-16 潍坊滨海石油化工有限公司 苯乙酸的制备方法
EA202091323A1 (ru) 2017-12-01 2020-10-09 Юсб Байофарма Срл Визуализирующие средства
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
IL289317B2 (en) * 2019-07-01 2025-09-01 UCB Biopharma SRL Tetrahydroisoquinoline derivative is transformed as a positive allosteric modulator d1
PH12021552825A1 (en) * 2019-07-01 2022-10-03 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
KR20230014706A (ko) * 2020-04-24 2023-01-30 더 리전츠 오브 더 유니버시티 오브 캘리포니아 Nurr1 수용체 조절제 및 이의 용도
CN111943930B (zh) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Lasmiditan的合成工艺
ES2976784T3 (es) * 2020-10-07 2024-08-08 Lilly Co Eli Derivados de fenil-3,4-dihidroisoquinolin-2(1H)-il-etan-1-ona como moduladores alostéricos positivos del receptor de dopamina D1
CA3198635A1 (en) * 2020-12-03 2022-06-09 UCB Biopharma SRL Octahydroisoquinolinyl derivatives
JP7798891B2 (ja) * 2020-12-18 2026-01-14 ユーシービー バイオファルマ エスアールエル Ｄ１陽性アロステリック調節因子としての置換テトラヒドロイソキノリン誘導体
US20240083925A1 (en) * 2020-12-18 2024-03-14 UCB Biopharma SRL Prodrugs of 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
ES3000719T3 (en) 2020-12-18 2025-03-03 UCB Biopharma SRL Dihydroisoquinolinyl derivatives
WO2022129267A1 (en) * 2020-12-18 2022-06-23 UCB Biopharma SRL Amorphous solid dispersions
CN117377470A (zh) 2021-03-08 2024-01-09 伊莱利利公司 美维达林和其他d1正向别构调节剂在幻觉和痴呆相关精神病的治疗中的用途
EP4304577A1 (en) 2021-03-09 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression
CN114671810B (zh) * 2022-03-21 2024-03-22 济南鸿湾生物技术有限公司 一种咪唑苯脲的制备方法
CN115611768B (zh) * 2022-11-14 2024-03-05 郑州大学 一种3,4-二氯苯腈的合成方法
CN118724764B (zh) * 2024-06-07 2025-11-18 绍兴文理学院 一种芳基伯磺酰胺类化合物的制备方法
CN119569653B (zh) * 2024-11-25 2026-04-14 滁州市庆云医药有限公司 一种罗沙司他中间体的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766131A (en) * 1980-10-17 1988-08-23 Pennwalt Corporation 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics
MXPA04005988A (es) 2001-12-19 2004-09-27 Lundbeck & Co As H 3,4-dihidro-1h-isoquinolin-2-il-derivados.
WO2005111025A1 (en) * 2004-04-29 2005-11-24 Aventis Pharmaceuticals Inc. 3-piperidinylisochroman-5-ols as dopamine agonists
CA2679735A1 (en) * 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor

Also Published As

Publication number Publication date
EP3204359B1 (en) 2020-07-01
US20170304292A1 (en) 2017-10-26
PL3204359T3 (pl) 2021-03-22
CY1123417T1 (el) 2021-12-31
HRP20201469T1 (hr) 2020-12-11
JP2017530185A (ja) 2017-10-12
HUE050664T2 (hu) 2020-12-28
CN107001278B (zh) 2020-11-24
WO2016055479A1 (en) 2016-04-14
ES2821821T3 (es) 2021-04-27
PT3204359T (pt) 2020-09-24
CA2963951C (en) 2023-02-28
LT3204359T (lt) 2020-10-12
EP3204359A1 (en) 2017-08-16
JP6622299B2 (ja) 2019-12-18
RS60933B1 (sr) 2020-11-30
CA2963951A1 (en) 2016-04-14
EA035544B1 (ru) 2020-07-03
BR112017007123B1 (pt) 2023-01-31
US10105359B2 (en) 2018-10-23
CN107001278A (zh) 2017-08-01
BR112017007123A2 (pt) 2017-12-19
DK3204359T3 (da) 2020-09-14
SI3204359T1 (sl) 2020-10-30

Similar Documents

Publication Publication Date Title
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201691582A1 (ru) Новые фармацевтические препараты
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
JO3512B1 (ar) مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690713A1 (ru) Гетероциклические соединения и их применения
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
IL248668A0 (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
IL252089A0 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
LT3210973T (lt) Heteroarilo junginiai, skirti akių ligų gydymui
EA201892264A1 (ru) Производные тетрагидроизохинолина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM